New York University Langone Medical Center
Laura and Isaac Perlmutter Cancer Center
New York, NY
Filters
Save & Share
Clear Filters
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Accepting patients
CLN-049
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Learn more- Tyrosine Kinase (TK) Inhibitor
- FLT3
- Phase 1
Accepting patients
ASTX030
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Learn more- DNMT1 Inhibitor
- Phase 2/3
Accepting patients
PedAL Screening
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Learn more- Phase 1/2
Accepting patients
PRT2527
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies
Learn more- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- Phase 1